These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32398962)

  • 21. Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome.
    van de Veerdonk FL; Netea MG; van Deuren M; van der Meer JW; de Mast Q; Brüggemann RJ; van der Hoeven H
    Elife; 2020 Apr; 9():. PubMed ID: 32338605
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lessons from the Italian COVID-19 frontline.
    Bellan M; Sainaghi PP; Gavelli F; Patrucco F; Avanzi GC; Pirisi M; Castello LM
    Minerva Med; 2020 Aug; 111(4):303-305. PubMed ID: 33032392
    [No Abstract]   [Full Text] [Related]  

  • 23. SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.
    Prete M; Favoino E; Catacchio G; Racanelli V; Perosa F
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397684
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytokine storm and use of anakinra in a patient with COVID-19.
    Nemchand P; Tahir H; Mediwake R; Lee J
    BMJ Case Rep; 2020 Sep; 13(9):. PubMed ID: 32933914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.
    Takami A
    Int J Hematol; 2020 Jul; 112(1):122-124. PubMed ID: 32399895
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 Disease.
    Ciavarella C; Motta I; Valente S; Pasquinelli G
    Molecules; 2020 Apr; 25(9):. PubMed ID: 32365556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
    Schett G; Sticherling M; Neurath MF
    Nat Rev Immunol; 2020 May; 20(5):271-272. PubMed ID: 32296135
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study.
    Li D; Chen Y; Liu H; Jia Y; Li F; Wang W; Wu J; Wan Z; Cao Y; Zeng R
    Signal Transduct Target Ther; 2020 May; 5(1):62. PubMed ID: 32371949
    [No Abstract]   [Full Text] [Related]  

  • 29. Therapeutic Cannabis and COVID-19: between opportunism and infoxication.
    Pascual Pastor F; Isorna Folgar M; Carvalho N; Carvalho F; Arias Horcajadas F
    Adicciones; 2020 Jul; 32(3):167-172. PubMed ID: 32717094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Not Available].
    Nau JY
    Rev Med Suisse; 2020 Apr; 16(689):706-707. PubMed ID: 32270943
    [No Abstract]   [Full Text] [Related]  

  • 31. Cytokine profile and disease severity in patients with COVID-19.
    Ghazavi A; Ganji A; Keshavarzian N; Rabiemajd S; Mosayebi G
    Cytokine; 2021 Jan; 137():155323. PubMed ID: 33045526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19.
    Zhang C; Wu Z; Li JW; Tan K; Yang W; Zhao H; Wang GQ
    J Med Virol; 2021 Mar; 93(3):1378-1386. PubMed ID: 33107641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy.
    George PM; Wells AU; Jenkins RG
    Lancet Respir Med; 2020 Aug; 8(8):807-815. PubMed ID: 32422178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection.
    Lechowicz K; Drożdżal S; Machaj F; Rosik J; Szostak B; Zegan-Barańska M; Biernawska J; Dabrowski W; Rotter I; Kotfis K
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32575380
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-β signalling in COVID-19 survivors.
    P KM; Sivashanmugam K; Kandasamy M; Subbiah R; Ravikumar V
    Life Sci; 2021 Feb; 266():118883. PubMed ID: 33316266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.
    Han H; Ma Q; Li C; Liu R; Zhao L; Wang W; Zhang P; Liu X; Gao G; Liu F; Jiang Y; Cheng X; Zhu C; Xia Y
    Emerg Microbes Infect; 2020 Dec; 9(1):1123-1130. PubMed ID: 32475230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulmonary Fibrosis in COVID-19 Survivors: Predictive Factors and Risk Reduction Strategies.
    Ojo AS; Balogun SA; Williams OT; Ojo OS
    Pulm Med; 2020; 2020():6175964. PubMed ID: 32850151
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pulmonary fibrosis secondary to COVID-19: a call to arms?
    Spagnolo P; Balestro E; Aliberti S; Cocconcelli E; Biondini D; Casa GD; Sverzellati N; Maher TM
    Lancet Respir Med; 2020 Aug; 8(8):750-752. PubMed ID: 32422177
    [No Abstract]   [Full Text] [Related]  

  • 39. COVID-19 and risk of pulmonary fibrosis: the importance of planning ahead.
    Gentile F; Aimo A; Forfori F; Catapano G; Clemente A; Cademartiri F; Emdin M; Giannoni A
    Eur J Prev Cardiol; 2020 Sep; 27(13):1442-1446. PubMed ID: 32551971
    [No Abstract]   [Full Text] [Related]  

  • 40. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis.
    Wilson JG; Simpson LJ; Ferreira AM; Rustagi A; Roque J; Asuni A; Ranganath T; Grant PM; Subramanian A; Rosenberg-Hasson Y; Maecker HT; Holmes SP; Levitt JE; Blish CA; Rogers AJ
    JCI Insight; 2020 Sep; 5(17):. PubMed ID: 32706339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.